Japan plans to revise its definition of “vaccines of high development priority.” The Ministry of Health, Labor and Welfare’s (MHLW)…
HOME > BUSINESS
BUSINESS
- Sales Rep Survey - Part 1: Number of Reps at Foreign Drug Makers Declines Sharply; Down by 330 at GSK
May 2, 2016
- 53 Drug Makers Hire 200 Less New Grads in FY2016, Japan Firms See Hefty Drop: Jiho Tally
April 28, 2016
- Kenji Sukeno to Become New Fujifilm Holdings President
April 28, 2016
- Nogimori to Bow Out as Astellas Chairman
April 28, 2016
- Kaken Licenses Severe Burn Treatment from Israeli Firm
April 27, 2016
- Biogen Eyes Simultaneous Filings in Japan, US, Europe for Alzheimer’s Drug Aducanumab
April 27, 2016
- Harvoni Most Prescribed Drug at Acute Hospitals in October-December
April 27, 2016
- Chugai, Hiroshima Univ. Spinoff Join Hands in Cartilage Regeneration
April 26, 2016
- Boehringer Japan’s Ethical Drug Sales Tick Up 2% in 2015
April 26, 2016
- Novartis Seeks Add’l Indications for Ilaris in Japan
April 26, 2016
- Novartis Looks to Harness Big Data for Indication Expansions: Global Medical Chief
April 26, 2016
- MSD, Sanofi to End RotaTeq, Heptavax Copromotion in Japan
April 25, 2016
- Janssen Files Simponi for Ulcerative Colitis in Japan
April 25, 2016
- Kaketsuken Continues to Suspend Production as Huge Damages Found
April 22, 2016
- Novo Nordisk’s Japan Sales Log Record 89 Billion Yen on Tresiba, Victoza
April 22, 2016
- Around 140 Clinical Trials of Nucleic Acid Drugs Underway Worldwide, with Cancer, Neuropathy, and Myopathy as Main Targets
April 22, 2016
- Mylan Japan Management, Labor Union Remain at Odds over Sales Rep Layoff
April 21, 2016
- Japan’s 1st PCSK9 Inhibitor Hits Market; MHLW Issues Notification to Prevent Hasty Use
April 21, 2016
- Ajinomoto Pulls Out from JV with Yoshindo as EA Pharma Launched
April 21, 2016
- MSD’s Hep C Drugs Get Priority Review Status in Japan
April 20, 2016
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…